tirzepatide shortage ending Eli Lilly's Weight-Loss Drug Zepbound Is Officially Over: FDA FDA says this weight loss

doi: 10.1016/S0140-6736(08)60269-X

The stop-start pattern of running out early, going without for several days, and then resuming creates more dramatic concentration swings than consistent weekly dosing, potentially worsening the very wearing-off effect that prompted the frequency increase in the first place

The headline that tirzepatide produces greater weight loss is consistent with everything we have seen, but individual results always vary

Escalation phase (roughly weeks 520): step up about every four weeks 5 7.5 10 12.5 15 mg but only as tolerated

Common side effects may include gastrointestinal discomfort, which often subsides as the body adjusts